Zepp Health Corporation (ZEPP) 주식 분석

회사 개요

Zepp Health Corporation operates globally as a smart wearable and health technology company, empowering users to optimize their health, fitness, and wellness journeys through its consumer brands including Amazfit, Zepp Clarity, and Zepp Aura. The company is situated within the Technology sector and specifically functions in the Consumer Electronics industry, a classification that denotes its focus on producing electronic devices for personal use rather than industrial machinery or software services. Zepp Health Corporation currently holds a market capitalization of $168.48M and reports an annual revenue of $258.90M, while the precise employee count is listed as N/A in available data. These valuation and revenue figures indicate that the company operates as a mid-cap entity with a significant revenue base relative to its market value, suggesting a business model where sales volume is substantial but market pricing reflects a specific risk premium or growth expectation inherent in the consumer electronics space.

재무 건전성

The company reported total revenue of $258.90M over the trailing twelve months, yet this revenue generated a net income of $-40,068,000 and an EBITDA of $-24,213,000, revealing a substantial gap between top-line sales and bottom-line profitability that points to a heavy cost structure or significant operating expenses consuming the majority of generated cash. While the free cash flow is listed as N/A, the company maintains a cash balance of $57.05M against total debt of $116.31M, indicating a leveraged balance sheet where liabilities exceed liquid assets available for immediate obligations. The debt-to-equity ratio stands at 54.21, further confirming that the capital structure is heavily reliant on debt financing rather than equity, which increases financial risk during periods of high interest rates or declining cash flow. Profitability metrics show a gross margin of 38.3%, an operating margin of -4.5%, and a profit margin of -15.5%, illustrating that while the company retains significant value after cost of goods sold, operational inefficiencies or high overhead costs severely erade earnings before interest and taxes, resulting in a net loss on every dollar of revenue. The current ratio of 1.02 suggests that the company's current assets are only marginally higher than its current liabilities, indicating a tight liquidity position where the firm must manage working capital extremely carefully to avoid short-term solvency issues. Return on Equity is -17.2% and Return on Assets is -3.3%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the asset base, signaling that operational strategies have yet to translate into efficient capital deployment or profitability improvements.

밸류에이션 평가

The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is reported as -1152.00, implying that analysts or market models project continued negative earnings or that valuation is currently being driven by revenue growth and intangible factors rather than current profitability. The price-to-book ratio is 0.85, indicating that the market values the company at a discount to its book value, which often suggests that the market perceives limited growth prospects or significant intangible asset risks that depress the valuation below the tangible asset base. Alternative valuation metrics such as the price-to-sales ratio of 0.65 and the EV/EBITDA of -123.31 provide further context, showing that the stock is priced at a fraction of its sales but with an enterprise valuation that is deeply negative relative to earnings, highlighting the disconnect between current revenue generation and the ability to generate cash flow to service debt. The stock has traded between a 52-week high of $61.85 and a 52-week low of $2.12, demonstrating extreme volatility and a wide trading range that reflects high investor sentiment swings or speculative trading activity rather than stable fundamental pricing. With a beta of 1.77, the stock exhibits price volatility that is significantly higher than the broader market, meaning that for every 1% move in the overall market, Zepp Health's stock price tends to move 1.77% in the same direction, amplifying both potential gains and losses for risk-tolerant participants.

Growth & Income

Zepp Health Corporation achieved a revenue growth year-over-year of 43.0%, whereas the earnings growth year-over-year is N/A due to the company's ongoing losses, indicating that the top line is expanding rapidly while profitability has not yet been realized, a common pattern in high-growth technology firms still burning cash to capture market share. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings (or in this case, the allocation of resources) are theoretically available for reinvestment or are currently being used to cover operating deficits rather than being distributed to shareholders. This lack of dividend payout aligns with the company's growth strategy, where capital is prioritized for research and development, manufacturing expansion, or marketing initiatives to solidify its position in the consumer electronics market rather than providing income to investors. Overall, the financial profile depicts a high-growth, non-dividend-paying entity characterized by strong revenue expansion but persistent profitability challenges and a leveraged balance sheet that requires careful monitoring of cash burn and debt servicing capabilities.